The impact of SARS-CoV2 has everyone trying to manage patient care with a sharp eye on resources. With a focus on OR efficiency, minimizing prolonged stays and reducing readmissions and preventable complications is vital to patient flow and facility economics. As you look for solutions that provide extended value, it may be time to consider how PREVENA™ Therapy protects you, your patients, and your practice well beyond the incision site.
PREVENA™ Therapy is the first and only medical device indicated by FDA to help reduce superficial surgical site infections in high-risk patients in Class I and II wounds*
PREVENA™ Therapy is uniquely engineered to empower incision management that works to protect patients, surgeons, staff, practices, and hospitals during the SARS-CoV-2 pandemic.
Your form was submitted successfully!
An error has occurred while submitting. Please try again.
*PREVENA™ 125 and PREVENA PLUS™ 125 Therapy Units manage the environment of closed surgical incisions and remove fluid away from the surgical incision via the application of -125mmHg continuous negative pressure. When used with legally marketed compatible dressings, PREVENA™ 125 and PREVENA PLUS™ 125 Therapy Units are intended to aid in reducing the incidence of seroma and, in patients at risk for post-operative infections, aid in reducing the incidence of superficial surgical site infection in Class I and II wounds.
The effectiveness of PREVENA™ Therapy in reducing the incidence of SSIs and seroma in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at myKCI.com.